131 related articles for article (PubMed ID: 26593678)
1. Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).
Das J
Expert Opin Ther Pat; 2016; 26(4):523-8. PubMed ID: 26593678
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C inhibitors: a patent review (2010 - present).
Sobhia ME; Grewal BK; Paul ML; Patel J; Kaur A; Haokip T; Kokkula A
Expert Opin Ther Pat; 2013 Nov; 23(11):1451-68. PubMed ID: 23795866
[TBL] [Abstract][Full Text] [Related]
4. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor.
Grodsky N; Li Y; Bouzida D; Love R; Jensen J; Nodes B; Nonomiya J; Grant S
Biochemistry; 2006 Nov; 45(47):13970-81. PubMed ID: 17115692
[TBL] [Abstract][Full Text] [Related]
5. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C inhibitors: a patent review (2008 - 2009).
Sobhia ME; Grewal BK; Ml SP; Patel J; Kaur A; Haokip T; Kokkula A
Expert Opin Ther Pat; 2013 Oct; 23(10):1297-315. PubMed ID: 23795914
[TBL] [Abstract][Full Text] [Related]
7. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Jirousek MR; Gillig JR; Gonzalez CM; Heath WF; McDonald JH; Neel DA; Rito CJ; Singh U; Stramm LE; Melikian-Badalian A; Baevsky M; Ballas LM; Hall SE; Winneroski LL; Faul MM
J Med Chem; 1996 Jul; 39(14):2664-71. PubMed ID: 8709095
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies.
Sobhia ME; Grewal BK; Bhat J; Rohit S; Punia V
Expert Opin Ther Targets; 2012 Mar; 16(3):325-44. PubMed ID: 22404224
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C.
Boije af Gennäs G; Talman V; Aitio O; Ekokoski E; Finel M; Tuominen RK; Yli-Kauhaluoma J
J Med Chem; 2009 Jul; 52(13):3969-81. PubMed ID: 19438240
[TBL] [Abstract][Full Text] [Related]
11. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
Deng X; S Gray N
Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
[TBL] [Abstract][Full Text] [Related]
12. Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β.
van Eis MJ; Evenou J; Schuler W; Zenke G; Vangrevelinghe E; Wagner J; von Matt P
Bioorg Med Chem Lett; 2017 Feb; 27(4):781-786. PubMed ID: 28131714
[TBL] [Abstract][Full Text] [Related]
13. Selective Modulation of Protein Kinase C α over Protein Kinase C ε by Curcumin and Its Derivatives in CHO-K1 Cells.
Pany S; Majhi A; Das J
Biochemistry; 2016 Apr; 55(14):2135-43. PubMed ID: 26983836
[TBL] [Abstract][Full Text] [Related]
14. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
16. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present).
Wenglowsky S
Expert Opin Ther Pat; 2013 Mar; 23(3):281-98. PubMed ID: 23289383
[TBL] [Abstract][Full Text] [Related]
18. Compound and compositions as TGR5 agonists: WO2012082947.
Raval S
Expert Opin Ther Pat; 2013 Apr; 23(4):531-6. PubMed ID: 23409864
[TBL] [Abstract][Full Text] [Related]
19. Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue.
Liberman Z; Plotkin B; Tennenbaum T; Eldar-Finkelman H
Am J Physiol Endocrinol Metab; 2008 Jun; 294(6):E1169-77. PubMed ID: 18430969
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase C α/βII and activation of c-Jun NH2-terminal kinase mediate glycyrrhetinic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells.
Song J; Ko HS; Sohn EJ; Kim B; Kim JH; Kim HJ; Kim C; Kim JE; Kim SH
Bioorg Med Chem Lett; 2014 Feb; 24(4):1188-91. PubMed ID: 24461294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
